Nanobiotix Files October 2025 Report (6-K)
Ticker: NBTX · Form: 6-K · Filed: Oct 15, 2025 · CIK: 1760854
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, pharmaceuticals
TL;DR
Nanobiotix filed a 6-K on Oct 15, 2025, confirming their 20-F annual report submission.
AI Summary
Nanobiotix S.A. filed a Form 6-K on October 15, 2025, to report its activities for the month of October 2025. The company, a pharmaceutical preparations firm, is based in Paris, France, and is subject to SEC Act of 1934 with file number 001-39777. This filing indicates they are submitting their annual reports under Form 20-F.
Why It Matters
This filing provides an update on Nanobiotix S.A.'s ongoing activities and regulatory compliance, which is important for investors monitoring the company's progress in the pharmaceutical sector.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Nanobiotix S.A. (company) — Registrant
- 001-39777 (dollar_amount) — SEC File Number
- October 2025 (date) — Reporting Period
- 20-F (document) — Annual Report Form
FAQ
What is the primary purpose of this Form 6-K filing by Nanobiotix S.A.?
The primary purpose is to report activities for the month of October 2025 and to indicate that the registrant files annual reports under cover of Form 20-F.
What is Nanobiotix S.A.'s SEC file number?
Nanobiotix S.A.'s SEC file number is 001-39777.
Where is Nanobiotix S.A. located?
Nanobiotix S.A. is located at 60 Rue de Wattignies, 75012 Paris, France.
What is the SIC code for Nanobiotix S.A.?
The Standard Industrial Classification (SIC) code for Nanobiotix S.A. is 2834, which corresponds to Pharmaceutical Preparations.
Does Nanobiotix S.A. file its annual reports under Form 20-F or Form 40-F?
Nanobiotix S.A. files its annual reports under cover of Form 20-F.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-10-15 06:00:10
Filing Documents
- f6k_101425.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-25-006427.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: October 15, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer